课题基金 / 基金详情

Core 3

Core 3
核心3
批准号:
7314844
负责人:
Massimo Loda
金额:
$26.3万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-07-01 至 2012-06-30

项目摘要

项目成果

Massimo Loda的其他基金

相似基金

相关文献

中文摘要
翻译
DF/HCC前列腺癌孢子组织和病理学核心已经并将继续提供 合作研究者提供多种病理学服务,包括组织学、免疫组织化学、原位 杂交、荧光原位杂交(FISH)、计算机辅助图像分析、激光捕获 显微切割,以及组织微阵列(TMA)的产生和获取。我们的首要目标是 在达纳人中广泛的现有组织资源之间建立无缝的信息学联系, Farber/哈佛癌症中心(DF/HCC)医院和合作者。因此,本项目的主要目标之一是 核心是维持和生长现有的组织和血液资源(以下称为“生物库”), 与临床结果数据相关联,支持DF/HCC可用的安全数据管理系统 SPORE调查员以及其他机构的SPORE调查员。在这方面, 继续保持组织和病理学核心与生物统计学之间的密切合作, 计算生物学核心。 现列出该核心的指导原则: 1)成功的转化研究需要广泛的注释良好的人类分析物,小鼠分析物, 模型、异种移植物和细胞系。 2)患者保护和监管问题是任何生物库的首要任务。 3)在执行之前,需要确定样品的访问权限和使用规则(管理) 实验 4)每个样本生成的数据都会增加该样本的价值。 5)生物库应促进合格研究者的研究,无论他们是否隶属于 DF/HCC前列腺癌孢子(即,优秀的研究是鼓励从各个角落的 世界)。 6)应监测样品的分析前变异性,并采用标准操作规程(SOP) 在已知的情况下使用。 7)与现有计划的协同作用导致经济的努力。 8)鉴于资源有限,生物库应首先关注五个SPORE项目和 发展项目和职业发展获奖者的项目。 9)生物信息学增强了对生物库样本生成的数据的使用。
英文摘要
The DF/HCC Prostate Cancer SPORE Tissue and Pathology Core has provided and will continue to provide collaborating investigators multiple pathology services including histology, immunohistochemistry, in situ hybridization, fluorescent in situ hybridization (FISH), computer-assisted image analysis, laser capture microdissection, and the generation of and access to tissue microarrays (TMAs). Our overarching goal is to create a seamless informatics link between the extensive existing tissue resources among the Dana- Farber/Harvard Cancer Center (DF/HCC) hospitals and collaborators. Thus, one of the major goals of this Core is to maintain and grow an existing tissue and blood resource (henceforth referred to as "biobank"), linked to clinical outcome data, behind a secure data management system that will be available to DF/HCC SPORE investigators as well as SPORE investigators at other institutions. In this regard there is and will continue to be close collaboration between the Tissue and Pathology Core and the Biostatistical and Computational Biology Core. The guiding principles of this Core are now listed: 1) Successful translational research requires a wide range of well-annotated human analytes, mouse models, xenografts, and cell lines. 2) Patient protection and regulatory issues are the top priority of any biobank. 3) Access to samples and rules of usage (governance) need to- be determined prior to performing experiments. 4) Data generated from each sample increase that sample's value. 5) The biobank should facilitate research of qualified investigators regardless of their affiliation to the DF/HCC Prostate Cancer SPORE (i.e., outstanding research is encouraged from all corners of the world). 6) Pre-analytic variability of samples should be monitored and standard operating procedures (SOPs) should be employed when known. 7) Synergy with pre-existing programs leads to economy of effort. 8) Given limited resources, the biobank should focus first on the five SPORE Projects and the Developmental Projects and Projects of the Career Development Awardees. 9) Bioinformatics enhances the use of data generated from biobank samples.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Core A: Pathobiology Core
Core A: Pathobiology Core
Weill Cornell Medicine (WCM) SPORE in Prostate Cancer
Weill Cornell Medicine (WCM) SPORE in Prostate Cancer
海外基金